These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25137188)

  • 1. Childhood depression subscales using repeated sessions on Children's Depression Rating Scale - revised (CDRS-R) scores.
    Isa A; Bernstein I; Trivedi M; Mayes T; Kennard B; Emslie G
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):318-24. PubMed ID: 25137188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Impact of Treatment on the Dimensions of Childhood Depression.
    Isa A; Bernstein I; Trivedi M; Mayes T; Kennard B; Emslie G
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):160-166. PubMed ID: 26862813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
    Mayes TL; Bernstein IH; Haley CL; Kennard BD; Emslie GJ
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):513-6. PubMed ID: 21186970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric Properties and Factor Structures of the Korean Version of Children's Depression Rating Scale-Revised.
    Kim KM; Nam S; Choi JW; Jung AH; Hong SB; Kim JW; Kim SY; Kim E; Kim JW
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):285-292. PubMed ID: 28771381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.
    Jain S; Carmody TJ; Trivedi MH; Hughes C; Bernstein IH; Morris DW; Emslie GJ; Rush AJ
    J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1204-1212. PubMed ID: 17712244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Zhu L; Tao R; Hughes C; Croarkin P
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):21-8. PubMed ID: 22257126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
    Findling RL; McCusker E; Strawn JR
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
    [No Abstract]   [Full Text] [Related]  

  • 11. The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
    Amitai M; Taler M; Carmel M; Michaelovsky E; Eilat T; Yablonski M; Orpaz N; Chen A; Apter A; Weizman A; Fennig S
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):727-732. PubMed ID: 26771135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales.
    Zhang CY; Voort JLV; Yuruk D; Mills JA; Emslie GJ; Kennard BD; Mayes T; Trivedi M; Bobo WV; Strawn JR; Athreya AP; Croarkin PE
    J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):278-287. PubMed ID: 35704877
    [No Abstract]   [Full Text] [Related]  

  • 15. Systematic Review: The Measurement Properties of the Children's Depression Rating Scale-Revised in Adolescents With Major Depressive Disorder.
    Stallwood E; Monsour A; Rodrigues C; Monga S; Terwee C; Offringa M; Butcher NJ
    J Am Acad Child Adolesc Psychiatry; 2021 Jan; 60(1):119-133. PubMed ID: 33130251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
    McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
    J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.